



**BACTERIAL CELL DIVISION; A NOVEL
TARGET FOR NEW ANTIBACTERIALS**

Kennardy Dewanto Kusuma

January 2019

A thesis submitted in fulfilment of the requirements for the degree of
Doctor of Philosophy

Certificate of originality

I certify that the work in this thesis has not previously been submitted for a degree nor has it been submitted as part of requirements for a degree except as fully acknowledged within the text.

I also certify that the thesis has been written by me. Any help that I have received in my research work and the preparation of the thesis itself has been acknowledged. In addition, I certify that all information sources and literature used are indicated in the thesis.

I also verify that the research conducted for this thesis is supported by the Australian Government Research Training Program.

Production Note:

Signature removed prior to publication.

Kennardy D. Kusuma

August 2018

Acknowledgements

This PhD project has been a very long and exciting journey for me and I have many people to thank for that. First and foremost, I have to thank God for His grace and mercy in keeping my health and giving me the time to undertake this journey and see it through to completion. I would also like to thank my principal supervisor, Professor Liz Harry, as well as my secondary supervisors, Associate Professor Alison Ung and Dr Amy Bottomley. They have all constantly inspired me with their enthusiasm and passion for science. They have not only taught me how to be a better scientist but have also shaped me into the person that I am today. Their constant encouragement and advice on all things related to science and otherwise are words that have kept me going throughout this PhD project and I know that this PhD would not have been possible without their help. The three of them have been fantastic mentors throughout my research journey and I couldn't have asked for better supervisors. I would also like to thank the three of them in helping read and re-reading this thesis. Without their proof-reading efforts, I fear that this thesis would have been incomprehensible.

I would also like to thank the people of the Harry lab (past and present) for their friendship and assistance both in and outside the lab; Hajime, Sam, Leigh, Jaye, Mike S, Mike L, Andrew, Cath, Amy, Nural, Cindy, Isa, Shirin, Beth, Daniel, Riti and Liz P. You guys have made the lab such an amazing place to work! Your knowledge and passion for science is infectious and inspiring.

A special thanks to Iain Duggin and Amy for being great mentors in the early years of my PhD during protein purifications. Also, Nick Dixon, Aaron Oakley, Nan and Faye with all protein chemistry knowledge and the tricks of the trade. I would also like to thank Joel Mackay and Lorna White for their help and insights into the world of NMR and both David Jacques and Kate Michie for mentoring me in the art of protein

crystallization. I would also like to thank the university and the i3 institute for providing equipment and lab space for conducting experiments. I would also like to thank our collaborators overseas for providing strains and assistance. In particular, I would like to thank Professor Frederico José Gueiros Filho from the Universidade de São Paulo for providing the *B. subtilis* FtsZ mutant protein that allowed me to complete my PhD and submit this thesis.

On a personal note, I would like to thank my family; dad, mum, Fabian and Quentina for their continuous love and support, as well as reminders which constantly drives me to be the best that I can be. I owe a big thanks to my extended family of uncles, aunties and friends from Galilee Best Unity Church Inc. which have supported me and encouraged me along the way. I wouldn't even be here without your support.

Lastly, I would like to thank the Australian government for providing me with an Australian postgraduate award. Without this financial assistance, I would not have a roof over my head and meals would be limited to drinking water.

Table of Contents

Certificate of originality	I
Acknowledgements	II
Table of Contents	IV
List of Figures and Tables	X
Abbreviations	XVI
Publications	XIX
Abstract.....	XXI
 CHAPTER 1 - INTRODUCTION.....	 1
1.1 THE IDEAL ANTIBIOTIC	1
1.2 TARGETS OF CURRENTLY APPROVED ANTIBIOTICS	5
1.3 MECHANISMS OF RESISTANCE TO CURRENTLY APPROVED ANTIBACTERIAL	
AGENTS.....	10
<i>1.3.1 Modification of the target.....</i>	<i>10</i>
<i>1.3.2 Enzymatic inactivation</i>	<i>12</i>
<i>1.3.3 Efflux pumps</i>	<i>13</i>
<i>1.3.4 Reduced permeability</i>	<i>15</i>
<i>1.3.5 Possible solutions to antibiotic resistance.....</i>	<i>15</i>
1.4 CELL DIVISION AND DIVISION PROTEINS	18
1.6 FTSZ: THE PROKARYOTIC HOMOLOGUE OF TUBULIN	21
1.7 FTSA: AN ACTIN-LIKE FTSZ-INTERACTING PROTEIN	23
1.8 INTERACTION BETWEEN FTSZ AND FTSA.....	25
1.9 IS FTSZ A GOOD ANTIBACTERIAL TARGET?.....	27
1.10 INHIBITORS OF FTSZ: THE BENZAMIDE DERIVATIVES	31
1.10 THESIS AIMS	33

CHAPTER 2 - MATERIALS AND METHODS	43
2.1 MATERIALS	43
2.1.1 Chemicals	43
2.1.2 Solutions	44
2.1.3 Bacterial strains and plasmids	47
2.2 METHODS	56
2.2.1 DNA manipulation.....	56
2.2.1.1 Plasmid extraction.....	56
2.2.1.2 Preparation and transformation of electro-competent <i>E. coli</i>	56
2.2.1.3 PCR amplification of wild-type <i>B. subtilis</i> <i>ftsZ</i> ¹²⁻³¹⁵ gene.....	57
2.2.1.4 Restriction digest of the PCR product and plasmid.....	58
2.2.1.5 Ligation of the PCR product and plasmid.....	58
2.2.1.6 Colony PCR	59
2.2.2 Protein purification	59
2.2.2.1 Overproduction trial of <i>Acinetobacter</i> FtsZ and FtsA	59
2.2.2.2 Analysis of the <i>Acinetobacter</i> FtsZ and FtsA protein overproduction and solubility.....	60
2.2.2.4 Ammonium sulphate precipitation trial	61
2.2.2.5 Sodium chloride dialysis trial	62
2.2.2.6 Optimized purification protocol.....	62
2.2.3 Functional assays	68
2.2.3.1 GTPase assay using wild-type <i>B. subtilis</i> FtsZ ¹²⁻³¹⁵	68
2.2.4 Nuclear Magnetic Resonance.....	70
2.2.4.1 Competition experiment using HSQC	70
2.2.5 Crystallography.....	70

2.2.5.1 Setting up crystal trays.....	70
2.2.6 <i>Molecular modelling</i>	71
2.2.6.1 Creating a protein homology model of <i>Staphylococcus aureus</i> FtsZ and <i>Acinetobacter</i> FtsA	71
2.2.6.2 Assessing the validity of the homology models	72
2.2.6.3 Protein-protein interaction using docking.....	73
2.2.6.4 Superimposition of multiple crystal structures	74
2.2.6.5 Identification of Accessible Binding Spheres.....	75
2.2.6.6 Molecular Dynamics Simulations.....	75
 CHAPTER 3 - UNDERSTANDING THE INTERACTION OF <i>ACINETOBACTER</i> FTSZ AND FTSA USING <i>IN SILICO</i> METHODS	 77
3.1 INTRODUCTION	77
3.1.1 <i>Interaction between FtsZ and FtsA</i>	79
3.2 RESULTS: <i>IN SILICO</i> INVESTIGATION OF THE INTERACTION BETWEEN FTSZ AND FTSA IN <i>ACINETOBACTER</i>	82
3.2.1 <i>Analysis of full-length FtsZ amino acid sequence alignment to identify the conserved C-terminal peptide in Acinetobacter FtsZ</i>	82
3.2.2 <i>Accuracy validation of the 3D modelling program through the re-construction of the published Staphylococcus aureus FtsZ structure</i>	87
3.2.3 <i>In silico reconstruction of Acinetobacter spp. FtsA tertiary structure</i>	92
3.2.4 <i>In silico model of Acinetobacter spp. FtsZ and FtsA interaction</i>	97
3.3 DISCUSSION	103
 CHAPTER 4 – PROTEIN PURIFICATION OF FULL-LENGTH <i>ACINETOBACTER</i> FTSZ AND FTSA FOR <i>IN VITRO</i> INTERACTION STUDY	 108

4.1 INTRODUCTION	108
4.2 RESULTS: OVERPRODUCTION AND PURIFICATION OF THE FULL-LENGTH ACINETOBACTER FtsZ AND FtsA PROTEINS	110
4.2.1 <i>Overproduction and solubility analysis of Acinetobacter baumannii and Acinetobacter baylyi full-length FtsZ.....</i>	110
4.2.2 <i>Ammonium sulphate precipitation trial of untagged Acinetobacter full- length FtsZ.....</i>	114
4.2.3 <i>Purification trial of full-length Acinetobacter untagged FtsZ.....</i>	117
4.2.4 <i>Analysis and prevention of proteolysis of full-length A. baylyi untagged FtsZ during purification</i>	119
4.2.5 <i>Purification of full-length A. baylyi untagged FtsZ leading to X-ray crystallography trials</i>	122
4.2.6 <i>Crystallography trials using full-length A. baylyi untagged FtsZ.....</i>	123
4.2.7 <i>Overproduction analysis of full-length A. baylyi N-terminus and C- terminus hexa-histidine-tagged FtsA.....</i>	125
4.2.8 <i>Purification trial of full-length A. baylyi C-terminal hexa-histidine-tagged FtsA using nickel affinity chromatography</i>	129
4.2.9 <i>Concentrating full-length A. baylyi C-terminal hexa-histidine-tagged FtsA using various methods</i>	130
4.2.10 <i>Confirming full-length A. baylyi C-terminal hexahistidine-tagged FtsA polymeric state via size exclusion chromatography.....</i>	132
4.3 DISCUSSION	134
CHAPTER 5 - IN SILICO ANALYSIS OF FtsZ CRYSTAL STRUCTURES TO BETTER UNDERSTAND ITS POTENTIAL AS A DRUG TARGET	138
PREFACE	138

5.1 INTRODUCTION	138
5.2 RESULTS AND DISCUSSION: <i>IN SILICO</i> ANALYSIS OF FtsZ STRUCTURES FROM DIFFERENT BACTERIAL SPECIES	141
5.2.1 <i>Comparison of GDP-bound FtsZ structures from different bacterial species</i>	141
5.2.1.1 Superimposition of published FtsZ X-ray crystal structures	141
5.2.1.3 Comparison of accessible binding sites between GDP-bound FtsZs from various bacterial species.....	149
5.2.2 <i>Comparing GTP and GDP-bound FtsZ of various bacterial species</i>	154
5.2.2.1 Comparison of GTP- and GDP-bound FtsZ structures.....	154
5.2.2.2 Accessible binding site comparison of GTP- and GDP-bound non- staphylococcal FtsZ structures.....	157
5.2.3 <i>Molecular dynamics simulation.....</i>	161
5.3 CONCLUSION	167
CHAPTER 6 - FRAGMENT-BASED DRUG DISCOVERY USING FtsZ AS A TARGET.....	168
6.1 INTRODUCTION	168
6.1.1 <i>Inhibitors of FtsZ.....</i>	168
6.1.2 <i>Fragment-based drug discovery.....</i>	169
6.1.3 <i>Requirements for a successful FBDD project</i>	170
6.1.4 <i>Fragment-based drug screening using NMR.....</i>	171
6.1.5 <i>Producing compounds by fragment-linking and -growing.....</i>	173
6.2 RESULTS: FRAGMENT-BASED DRUG DISCOVERY USING <i>B. SUBTILIS</i> FtsZ AS THE TARGET	176

6.2.1 Bioinformatically identifying the mutation A182E on <i>B. subtilis</i> FtsZ structure.....	176
6.2.2 Initial fragment-based drug screening	177
6.2.3 TROSY-HSQC screen with ^{15}N labelled <i>B. subtilis</i> FtsZ ^{I-315} A182E	182
6.2.4 HSQC-NMR competition experiment using <i>B. subtilis</i> FtsZ ^{I-315} A182E...	184
6.2.5 Overproduction and purification of wild-type <i>B. subtilis</i> FtsZ ^{I2-315}	188
6.2.6 Functional assay using a GTPase kit with the wild-type <i>B. subtilis</i> FtsZ ^{I2-315}	192
6.2.7 Triple-ligand detect experiment using wild-type <i>B. subtilis</i> FtsZ ^{I2-315} to confirm the binding of the fragment 1, 3 and 14 to the wild-type protein.....	195
6.2.8 Crystallization of wild-type <i>B. subtilis</i> FtsZ ^{I2-315}	197
6.3 DISCUSSION	208
CHAPTER 7 - GENERAL DISCUSSION	214
CHAPTER 8 - REFERENCES	223

List of Figures and Tables

Figure 1.1: Pathways targeted by antibiotics	3
Figure 1.2: Timeline of antibiotic discovery	4
Figure 1.3: Mechanisms of lateral gene transfer	9
Figure 1.4: Vancomycin resistance mechanism of action	11
Figure 1.5: The working of the efflux pump complex TolC-AcrAB in <i>E. coli</i>	14
Figure 1.6: Schematic of <i>E. coli</i> and <i>B. subtilis</i> cell division	19
Figure 1.7: The <i>E. coli</i> cell division proteins and their partners that form the divisome	20
Figure 1.8: Crystal structure of <i>M. jannaschii</i> FtsZ and its ability to polymerise	23
Figure 1.9: The crystal structures of FtsA from <i>T. maritima</i> and actin..	25
Figure 1.10: Structural comparison of <i>S. aureus</i> FtsZ and human α-tubulin	29
Figure 2.1: Standard curve of known phosphate concentration vs absorbance at 650 nm	68
Figure 2.2: An example of a well set up in the 96-welled MRC plate for crystallography	71
Figure 3.1: Crystal structure of FtsA from <i>T. maritima</i> bound to FtsZ C-terminal peptide	80
Figure 3.2: Full-length FtsZ amino acid sequence alignment using Clustal Omega	83
Figure 3.3: Peptide location affects linker length	86

Figure 3.4: Superimposition of <i>S. aureus</i> FtsZ homology model to that of the <i>S. aureus</i> FtsZ X-ray crystal structure using Discovery Studio 4.5	91
Figure 3.5: Homology modeling workflow in Discovery Studio 4.5	92
Figure 3.6: 3D-Profile Verification of the <i>Acinetobacter</i> spp. homology FtsA model using Discovery Studio 4.5	96
Figure 4.1: <i>A. baylyi/baumannii</i> untagged FtsZ purification workflow	113
Figure 4.2: Ammonium sulphate precipitation trials of untagged <i>A. baumannii</i> and <i>A. baylyi</i> FtsZ	115
Figure 4.3: Testing of untagged <i>A. baumannii</i> and <i>A. baylyi</i> FtsZ stability in a range of sodium chloride concentrations	116
Figure 4.4: Testing gel filtration method using <i>A. baylyi</i> and <i>A. baumannii</i> untagged FtsZ revealed a double band	117
Figure 4.5: <i>A. baylyi</i> untagged FtsZ purification	120
Figure 4.6: Test to see if proteolysis happens during cell lysis for <i>A. baylyi</i> FtsZ	121
Figure 4.7: Successful <i>A. baylyi</i> untagged FtsZ purification	123
Figure 4.8: Microcrystal formation of <i>A. baylyi</i> untagged full-length FtsZ	125
Figure 4.9: Overproduction screening of full-length <i>A. baylyi</i> N-terminus and C-terminus hexa-histidine-tagged FtsA	127
Figure 4.10: <i>A. baylyi/baumannii</i> N- and C-hexahistidine tagged FtsA purification workflow	128
Figure 4.11: Inclusion bodies purification trial of N-terminus and C-terminus his-tagged <i>A. baylyi</i> full-length FtsA from 1L culture ...	128

Figure 4.12: Purification trial of <i>A. baylyi</i> C-terminal hexahistidine-tagged full-length FtsA	130
Figure 4.13: Concentrating full-length <i>A. baylyi</i> C-terminal hexahistidine-tagged FtsA via dialyzing against PEG 20,000	132
Figure 5.1: Druggable regions of FtsZ	140
Figure 5.2: Superimposition of FtsZ from various organisms and of FtsZ structures with human α- and β-tubulin	143
Figure 5.3: Comparison of druggable pocket sizes between FtsZ from different organisms	147
Figure 5.4: Comparison of the accessible binding sites of various GDP-bounded FtsZ structures	152
Figure 5.5: Amino acid sequence alignment of the T6-loop from multiple bacterial species using Clustal Omega	153
Figure 5.6: Analysis of the accessible binding sphere of <i>S. aureus</i> FtsZ when bound to different nucleotides and the FtsZ inhibitor PC190723	157
Figure 5.7: A model of structural changes in monomeric FtsZ upon binding to GDP and GTP	160
Figure 5.8: Conformational change of <i>B. subtilis</i> FtsZ	162
Figure 5.9: Conformational change of <i>S. aureus</i> FtsZ when bound to nucleotides and an inhibitor	165
Figure 5.10: Conformational change of <i>S. aureus</i> FtsZ	166
Figure 6.1: Chemical structure of Vemurafenib and Venetoclax	171
Figure 6.2: Examples of antibacterials that were developed from fragment-based drug discovery	171

Figure 6.3: Typical schematic of fragment-based drug discovery	173
Figure 6.4: The process of fragment linking	174
Figure 6.5: The process of fragment growth	174
Figure 6.6: Indication of the A182E mutation position in the <i>B. subtilis</i> FtsZ	177
Figure 6.7: Cut-off value for determining “hit” fragments in the triple- ligand detect experiments	180
Figure 6.8: Mapping the binding location of the four hit fragments on the <i>B. subtilis</i> FtsZ crystal structure	183
Figure 6.9: An example spectrum showing fragment binding to <i>B.</i> <i>subtilis</i> FtsZ ¹⁻³¹⁵ A182E	186
Figure 6.10: The preferred binding site of fragment 1, 3 and 14 on the <i>B. subtilis</i> FtsZ ¹⁻³¹⁵ A182E	187
Figure 6.11: Overproduction of wild-type <i>B. subtilis</i> FtsZ ¹²⁻³¹⁵	189
Figure 6.12: Chromatogram and SDS-PAGE of size exclusion chromatography during the purification of wild-type <i>B. subtilis</i> FtsZ ¹²⁻³¹⁵	191
Figure 6.13: Concentrated protein sample of wild-type <i>B. subtilis</i> FtsZ ^{12- 315} from peak 1 and peak 2	192
Figure 6.14: Testing the protein sample for phosphate contamination using malachite green	193
Figure 6.15: Calculated GTPase specific activity of wild-type <i>B. subtilis</i> FtsZ ¹²⁻³¹⁵ at different protein concentrations	195
Figure 6.16: Diffraction pattern produced by wild-type <i>B. subtilis</i> FtsZ ¹²⁻³¹⁵ crystal	203

Figure 6.17: Optimization of crystallization condition of wild-type <i>B. subtilis</i> FtsZ¹²⁻³¹⁵ protein resulted in the increase of crystal size	204
Figure 6.18: The effect of using 20% glycerol as a cryoprotectant to the crystal diffraction pattern	207
Table 1.1: Current reported inhibitors of FtsZ and experimental evidence provided	35
Table 2.1: Antibiotic sources and their working concentration for <i>E. coli</i>	43
Table 2.2: Media used in this study	43
Table 2.3: Solutions used in this study	44
Table 2.4: Bacterial strains used in this study	47
Table 2.5: Plasmids used and constructed in this study	53
Table 2.6: Primers used for the PCR amplification of <i>B. subtilis</i> FtsZ¹²⁻³¹⁵	57
Table 2.7: The molecular weight, pI and extinction coefficient of proteins used in this study	67
Table 3.1: <i>S. aureus</i> FtsZ homology model analysis	90
Table 3.2: <i>Acinetobacter</i> spp. FtsA homology model analysis	95
Table 3.3: Simulated interactions of <i>T. maritima</i> FtsZ to <i>A. baumannii</i>/<i>baylyi</i> FtsA	99
Table 4.1: Examination of strains and induction temperatures to overproduce soluble <i>A. baumannii</i> and <i>A. baylyi</i> FtsZ	112
Table 5.1: RMSD values obtained from the superimposition of FtsZ and tubulin structures	144
Table 5.3: FtsZ structural differences between the GDP- and GTP-bound states	155

Table 6.1: Mutant <i>B. subtilis</i> FtsZ amino acid residues which changed upon fragment binding during the TROSY-HSQC experiment.....	182
Table 6.2: Amino acid of mutant <i>B. subtilis</i> FtsZ which experienced a change in their signals upon the addition of fragments and GDP.....	185
Table 6.3: Comparison of triple-ligand detect experimental data between mutant and wild-type <i>B. subtilis</i> FtsZ protein.....	197
Table 6.4: Conditions which were identified to produce <i>B. subtilis</i> FtsZ¹²⁻³¹⁵ crystal with sharp edges.....	199
Table 6.5: Cell dimension of the crystal form pursued in this study	205

Abbreviations

°C	Degrees Celcius
μ	Micro (10 ⁻⁶)
¹⁵ N	Nitrogen 15
Å	Angstrom
ADP	Adenosine 5'-diphosphate
Amp ^r	Ampicillin resistance
APS	Ammonium per sulfate
ATP	Adenosine 5'-triphosphate
bp	Base pair(s)
cm	centimeter
Cα	alpha carbon
Da	Dalton(s)
DNA	Deoxyribose nucleic acid
dNTPs	deoxyribonucleotide triphosphate
DTT	Dithiothreitol
FD	Faraday constant
<i>fts</i>	Filamentous temperature sensitive
g	Gram(s)
GDP	Guanosine 5'-diphosphate
GTP	Guanosine 5'-triphosphate
h	Hour(s)
HEPES	(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid)
IPTG	Isopropyl-1-thio-β-D-galactopyranoside
K	Kelvin

Kan ^r	Kanamycin resistance
kb	Kilobase(s)
K _d	Dissociation constant
kDa	Kilo (10 ³)
L	Liter
LB both	Luria-Bertani broth
m	Milli (10 ⁻³)
M	Moles per Liter (Molar)
min	Minute(s)
MTS	Membrane targeting sequence
MWCO	Molecular weight cut off
n	Nano (10 ⁻⁹)
NBD	nucleotide-binding domain
OD _(x)	Optical density measured at x nanometer wavelength
p	Probability
PCR	Polymerase chain reaction
PEG	Poly-ethylene glycol
PMSF	Phenylmethylsulfonyl fluoride
ps	Picosecond
R	resolution
RMSD	root mean square deviation
RNA	Ribonucleic acid
rpm	Revolution per minute
rRNA	Ribosomal ribonucleic acid
SDS	Sodium dodecyl sulphate

SDS-PAGE	Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
sec	Second(s)
STD-NMR	Saturated transfer difference nuclear magnetic resonance
TEMED	Tetramethylethylenediamine
Tet ^r	Tetracycline resistance
Tris	Tris(hydroxymethyl)methylamine
TROSY-HSQC	Transverse relaxation optimized spectroscopy-heteronuclear single quantum coherence
U	Units (enzyme activity)
V	Volts
v/v	Volume per volume
w/v	Weight per volume
Xg	Times gravity
Ω	Ohms

Publications

Journal articles

Bottomley AL, Liew ATF, **Kusuma KD**, Peterson E, Seidel L, Foster SJ, et al. Coordination of Chromosome Segregation and Cell Division in *Staphylococcus aureus*. Frontiers in Microbiology. 2017;8(1575).

Kusuma KD, Griffith R, Harry EJ, Bottomley AL, Ung AT. *In silico* Analysis of FtsZ Crystal Structures Towards a New Target for Antibiotics. Australian Journal of Chemistry. 2018

Conference proceedings

Kusuma KD, Amy Bottomley, Alison Ung, Aaron Oakley, Nick Dixon, Nan Li, Elizabeth Harry (**2015**) Cell division as a new target for the development of antibiotics against *Acinetobacter*, **East Coast Protein Meeting, Brisbane, Poster presentation.**

Kusuma KD, Amy Bottomley, Elizabeth Harry, Renate Griffith, Alison Ung (**2017**) Understanding FtsZ as an antibacterial target, **Solution for Drug-Resistant Infections Conference, Brisbane, Poster presentation.**

Abstract

The problem of antibiotic resistance is a complex issue and one that urgently needs addressing from multiple sectors, including agriculture, medicine, science/research, government, social science, businesses and the community. Although many strategies are being implemented around the world to address these different aspects that contribute to the rise and spread of antibiotic resistance, one further possibility to help alleviate this problem is through the design of novel antibiotics. The essential process of bacterial cell division, is yet to be targeted by any of the FDA-approved antibiotics and represents an untapped area of potential drug targets. In this thesis, the overall strategy of inhibiting the bacterial cell division process is to target the essential and conserved protein FtsZ in two ways: Firstly, to understand the essential interaction of FtsZ with another division protein, FtsA as a starting point to design inhibitors of division complex formation and, secondly, to develop compounds that inhibit FtsZ function.

Characterizing the protein-protein interaction of FtsZ and its partner FtsA used the proteins from the organism *Acinetobacter* spp.. This is because *A. baumannii* is now classified by the World Health Organization as a priority 1 pathogen that urgently needs an antibiotic against due to its high multidrug resistance profile, as well as causing high mortality rates. Two of the most highly conserved bacterial cell division proteins, FtsZ and FtsA, have been recognised as promising drug targets in *Acinetobacter* spp. and other bacteria. The interaction of these two proteins has been known for over a decade with mutational studies indicating that the conserved aspartate and proline at the extreme C-terminal peptide of FtsZ being the important amino acid residues for the interaction of FtsZ and FtsA in *Escherichia coli* and other bacterial species. Co-crystallography of *Thermotoga maritima* FtsZ C-terminal peptide and FtsA identified

an additional amino acid; arginine, to be important in the interaction of FtsZ and FtsA. In the *Acinetobacter* spp. the aspartate, proline and arginine have been changed to a serine, glutamine and lysine, respectively. Understanding this could potentially be used to develop new narrow-spectrum antimicrobials to specifically treat *Acinetobacter* infections. The work in this thesis attempted to understand the implication of these amino acid differences by initially conducting an *in silico* study. The data obtained suggests that the serine, glutamine and lysine are important for the FtsZ/FtsA interaction of *Acinetobacter* spp. Further follow up co-crystallographic studies were planned using full-length *Acinetobacter* FtsZ and FtsA. Both of these full-length *Acinetobacter* proteins were successfully purified in this study but, the purified FtsZ protein was unable to form crystals of acceptable size for structure determination, while the purified FtsA were found to be aggregated. Therefore, in the interest of time and for gaining positive results, the focus of the project was shifted towards solely understanding and targeting FtsZ.

Thus far, many published FtsZ inhibitors have been shown to target FtsZ in one of the three druggable regions on the protein: nucleotide-binding domain, interdomain cleft and T7-loop. A missing piece of information is an in-depth understanding of FtsZ structure at the molecular level across diverse bacterial species to ensure inhibitors have high affinity for the FtsZ target in a variety of clinically relevant pathogens. To address this, an *in silico* investigation was conducted by analysing multiple FtsZ structures, which revealed that FtsZ groups into two distinct classes based on structural differences. The outcome of this analysis lead to the suggestion of several binding pockets on FtsZ which can potentially be used as a broad- and narrow-spectrum target. The use of fragment-based drug discovery approach, allowed the confirmation of one of the suggested pockets, which is located towards the front of the nucleotide-binding domain.

This pocket is yet to be reported in the literature, therefore, allowing the possibility of novel drug design to contribute in tackling the global issue of antimicrobial resistance.